

DAFTAR PUSTAKA

- Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA, Molecular profile of colorectal cancer in Indonesia: is there another pathway?, *Gastroenterol Hepatol Bed Bench*, 2012 Spring; 5(2): 71-78
- American Cancer Society, 2015, Cancer Immunotherapy, (Online), <http://www.cancer.org/acs/groups/cid/documents/webcontent/003013-pdf.pdf> diakses 25 Maret 2016).
- American Cancer Society, 2015, Colorectal Cancer, (Online), <http://www.cancer.org/acs/groups/cid/documents/webcontent/003096-pdf.pdf>, diakses 22 Mei 2016)
- American Society of Clinical Oncology, 2015, Colorectal Cancer- Treatment Options (Online), (<http://www.cancer.net/cancer-types/colorectal-cancer/treatment-options>, diakses 9 Juni 2016)
- Ames BN, Gold LS, The Causes and Prevention of Cancer: The Role of Environment, *Biotherapy*, 1998, 11: 205-220
- Auyang SY, Cancer causes and cancer research on many levels of complexity, (Online), (<http://www.creatingtechnology.org/biomed/cancer.pdf>, diakses 3 Maret 2016)
- Bardhan K dan Liu K, Epigenetics and Colorectal Cancer Pathogenesis, *Cancers*, 2013, 5, 676-713
- Bell K, Twiggs J, Olin BR, *The Silent Killer: Updated JNC-8 Guideline Recommendation*, Alabama Pharmacy Association, 2015, Alabama
- Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, *et al.* Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemo-naïve patients with stage III/IV non-small-cell-lung cancer. *J Thorac Oncol*, 2013, 8(3):338-45
- Cai J, Ma H, Huang F, Zhu D, Bi J, *et al.* Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis, *World Journal of Surgical Oncology*, 11:306
- Chabner BA dan Longo DL (eds.), *Cancer Chemotherapy and Biotherapy: Principles and Practice*, 5th Edition, Wolters Kluwer: Lipincott Williams & Wilkins, 2011, Philadelphia p.499-500

- Chen J, Lu Y, Zheng Y, Incidence and Risk of Hypertension with bevacizumab in non-small-cell cancer patients: a meta-analysis of randomized controlled trials, *Drug Design, Development, and Therapy*, 2015,(9): p. 4751-4760
- Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, *et al*, Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab, *American Society of Clinical Oncology*, 29(6): p.632-638
- Dahlan MS, *Besar Sampel dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran dan Kesehatan*, Edisi 3, Salemba Medika, 2010, Jakarta, p.68-71
- Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH, Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599. *Journal of Clinical Oncology*, 2010, 28(6):p.949-954
- Di Bartolomeo M, Maggi C, Richhini F, Pietrantonio F, Iacovelli R, *et al.*, Bevacizumab treatment in the elderly patient with metastatic colorectal cancer, *Clin Intery Aging*, 10: 127-133
- Dragovich T, Tsikitis V L, Talavera F, Espat NJ, Schulman P, 2016, Colon Cancer, (Online), (<http://emedicine.medscape.com/article/277496-overview#a5>, diakses 22 Mei 2016).
- Dranitsaris S, Edwards S, Edwards J, Leblanck M, Abbott R, 2010, Bevacizumab in combination in FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador, *Curr Oncol*, 2010, 17(5): 12-16
- Ellis LM, Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer, *Semin Oncol*, 2006, 33(5 Suppl 10):S1-7
- Escudier B, Cosaert J, Jethwa S, Targeted therapies in the management of renal cell carcinoma: role of bevacizumab, *Biologics*, 2008, 2(3): 517-530
- European Medicines Agency, 2013, Annex I Summary of Product Characteristics: Avastin,(Online),(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf diakses 31 Maret 2016)
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, 2010, *Int. J. Cancer*:127, 2893-2917
- Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S, Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study, *International Journal of Hypertension*, 2013, 1-10

- Grossman A, Messerli FH, Grossman E, 2015, Drug induced hypertension-An unappreciated cause of secondary hypertension, *European Journal of Pharmacology*, 2015, 763(A): 15-22
- Hayman SR, Leung N, Grande JP, Garovic VD, VEGF inhibition, hypertension, and renal toxicity, *Curr Oncol Rep*, 2012, 14(4): 285-294
- Hoffman-La Roche, A study of first line treatment with Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer, (Online), (<https://clinicaltrials.gov/ct2/show/NCT00937560>, diakses 27 Maret 2016)
- Kominfo Jatim, 2011, Tercatat 160 Ribu Penderita Kanker, (Online), (<http://kominfo.jatimprov.go.id/read/gubernuran/664> diakses 22 Februari 2017).
- Liu XY, Pestka S, Shi YF, Recent Advances in Cancer Research and Therapy, Elsevier, 2012, London, p.312
- Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, *et al*, Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer, *N Engl J Med*, 2014, 371:1609-18
- Milazzo V, Di Stefano C, Servo S, Crudo V, Fulcheri C, *et al*, Drugs and Orthostatic Hypotension: Evidence from Literature, *J Hypertens*, 1:104
- Mohelnikova-Duchonova B, Melichar B, Soucek P, FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy, *World J Gastroenterol*, 20(30): 10316-10330
- Montero AJ, Escobar M, Lopes G, Gluck S, Vogel C, Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe, *Curr Oncol Rep*, 2012, 14(1):1-11
- Mukherji SK, Bevacizumab (Avastin), *American Journal of Neuroradiology*, 2010, 31: 235-236
- National Cancer Institute, FDA Approval for Bevacizumab, (Online), (<http://www.cancer.gov/about-cancer/treatment/drugs/fda-bevacizumab>, diakses 26 Maret 2016)
- National Heart Foundation of Australia, Guideline for the diagnosis and management of hypertension in adults, 2016, Melbourne: National heart Foundation of Australia
- Naz A, Najam R, Riaz B, Ahmed A, Evaluation of intravitreal bevacizumab for its systemic side effect thrombosis after chronic administration, *J App Pharm*, 2014, 6(2): 202-209

- Ohtani T, Hata E, Wakushima B, Moriki K, Iwai C, *et al.*, Blood Pressure Elevation in Patients Undergoing FOLFOX/FOLFIRI Therapy, *Jpn. J. Pharm. Health Care Sci.*, 2011,37(6); 327-333
- Osterlund P, Soveri L-M, Isoniemi H, Poussa T, Alanko T, Bono P, Hypertension and overall survival in metastatic colorectal patients treated with bevacizumab-containing chemotherapy, *British Journal of Cancer*, 2011, 104: 599 – 604
- Pande A, Lombardo J, Spangenthal E, Javle M, Hypertension Secondary to Anti-angiogenic Therapy: Experience with Bevacizumab,2007, *Anticancer Research*, 2007, 27:3465-3470
- Pavlidis E T dan Pavlidis T E, Role of bevacizumab in colorectal cancer growth and its adverse effects: A review, *World Journal of Gastroenterology*, 2013, 19(31): 5051-5060
- Ranpura V, Pulipati B, Chu D, Zhu X, Wu S, 2010, Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta analysis, (Online), (<http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010003841>, diakses 24 Februari 2015)
- Sander M, Chavoshan B, Victor RG, A Large Blood Pressure-Raising Effect of Nitric Oxide Synthase Inhibition in Humans, *Hypertension*, 1999, 33:937-942
- Shih T dan Lindley C, Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies, *Clinical Therapeutics*, 2006, 28(11): 1779-1802
- Siegel RL, Miller KD, Jemal A. Cancer Statistics 2015. *CA Cancer J Clin*, 2015, 65:5-29
- Souza VB, Silva EN, Ribeiro ML, Martins WA, Hypertension in Patients with Cancer, *Arq Bras Cardiol*, 2015, 104(3): 246-252
- Stefano AD, Moretto R, Cella CA, Romano FJ, Raimondo L, *et al.*, Bevacizumab maintenance in metastatic colorectal cancer: How long?, *World J Clin Cases*, 2014, 2(11): 717-723
- Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-Induced Hypertension. *Biodrugs*, 2011,25 (3): 159-169
- Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, *et al.*, Improved Survival with Bevacizumab in Advanced Cervical Cancer, *N Engl J Med*, 2014:370, 734-743
- Tol J, Cats A, Mol L, Koopman M, Bos MEM, van der Hoeven JJM, *et al.*, Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation, *Invest New Drugs*, 2008, 26:393-397

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, Global Cancer Statistics 2012, *Ca Cancer J Clin*, 2015,65:87-108

Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM, Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?, *The Oncologist*, 2010,15: 130-141

Vasudev NS, dan Reynolds AR, Anti-angiogenic therapy for cancer: current progress, unresolved questions, and future directions, *Angiogenesis*, 2014, 17:471-494

Vokes EE, Salgia R, Karrison TG, Evidence-based role of bevacizumab in non-small cell lung cancer, *Ann Oncol*, 2013, 24(1): 6-9

Wu RR, ;Lindenberg PA, Slack R, Noone AM, Marshall JL, *et al.*, Evaluation of Hypertension as a Marker of Bevacizumab Efficacy, *J Gastrointest Cancer*, 2009, 40(0): 101-108

Zhao CX, Xu X, Cui Y, Wag P, Wei X, *et al.*, Increased Endothelial Nitric-Oxide Synthase Expression Reduces Hypertension and Hyperinsulinemia in Fructose-Treated Rats, *The Journal of Pharmacology and Experimental Therapeutics*, 2009, 328(2): 610-620

